Opinion|Videos|December 2, 2024
Fezolinetant Guidelines and Emerging Data on Menopause and Liver Health
Panelists discuss why a warning about serious liver injury was added to the prescribing information for fezolinetant following a postmarketing case of drug-induced liver injury, and review updated guidelines for baseline liver testing, recommended monitoring, symptoms indicating the need to discontinue the medication, and key points for addressing patient concerns about liver health.
Advertisement
Episodes in this series
- Why was a warning about serious liver injury added to the prescribing information for fezolinetant? (ie, postmarketing case of drug-induced liver injury)
Note: Clarify that when fezolinetant first came out, it had guidelines for baseline liver testing. But in the past month, this was updated- discuss update and what this means for patients/ physicians.
- What baseline hepatic laboratory tests are recommended before patients start fezolinetant, and how often should they be monitored?
- What symptoms or clinical laboratory values indicate that fezolinetant should be discontinued?
- What are important discussion points to address patient concerns on liver health?
Advertisement
Related to this article
Maternal RSV immunization creates an important opportunity for obstetric and pediatric clinicians to coordinate newborn prevention strategies, according to Kevin Ault, MD.
A new Gallup survey found 51% of women in the United States reported negative healthcare experiences.
Hugh Taylor, MD, explains that imaging in endometriosis is best for ruling out other causes of pelvic pain and cannot exclude the diagnosis.
A new study links earlier menopause age to faster cognitive decline and earlier Alzheimer diagnosis.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, weighs his own experience with pellet therapy against guideline evidence, then he and Maria Uloko, MD, close with candid advice for clinicians too afraid of hormones to start prescribing.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, and Maria Uloko, MD, walk through real-world dosing, cost workarounds, and the labs that actually matter for safety and efficacy.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, and Maria Uloko, MD, reframe testosterone candidacy around clinical presentation and hormone state, not age cutoffs or a single number on a chart.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Earlier menopause associated with less favorable functional, structural neurological outcomes
2
FDA holding public meeting on testosterone use in menopausal women
3
Off-label testosterone dosing, access, and lab monitoring in the US
4
Pellet therapy and practical advice for hesitant prescribers
5